肝癌患者接受免疫检查点抑制剂或酪氨酸激酶抑制剂时乙型肝炎病毒再激活风险的比较
基于香港全港电子数据库,纳入2015年3月至2023年3月接受全身治疗的当前或既往HBV感染的肝癌患者1596例(222例首选ICI,1374例首选TKI)。中位随访10.7个月,25例(1.6%)发生HBVr,12个月累积发生率1.7%(95%CI 1.1%-2.4%)。多变量分析显示ICI使用与TKI相比未增加HBVr风险,不同ICI类型对HBVr风险无影响。结论:在充分抗病毒预防下,接受ICI的晚期HBV相关肝癌患者HBVr绝对风险低。
要点
- ICI与TKI相比未显著增加HBVr风险,不同ICI类型间风险无差异。
- 整体HBVr绝对风险低,12个月累积发生率1.7%(95%CI 1.1%-2.4%)。
- 接受抗病毒预防者HBVr比例为1.4%,未预防者为3.7%。
核心结论
- 在充分抗病毒预防下,接受ICI的晚期HBV相关肝癌患者HBVr绝对风险低,无论当前或既往HBV感染。
研究设计与样本
- 基于香港全港电子数据库的回顾性队列研究,纳入2015年3月至2023年3月接受全身治疗的当前或既往HBV感染肝癌患者1596例。
主要发现
- 中位随访10.7个月(IQR 3.7-12.0),25例(1.6%)发生HBVr,其中5例暴露于ICI。
- 1596例患者12个月HBVr累积发生率为1.7%(95%CI 1.1%-2.4%)。
- 接受和未接受抗病毒预防的患者HBVr比例分别为1.4%和3.7%。
- 多变量分析中,ICI使用与TKI相比未与更高的HBVr风险相关,不同ICI使用未影响HBVr风险。
关键数值与推荐
- HBVr定义依据美国肝病研究学会(AASLD)标准。
- 队列中93.2%的患者基线时接受HBV抗病毒预防。
- 205例(12.8%)为既往HBV感染。
临床怎么用
- 对接受ICI的晚期HBV相关肝癌患者,应确保充分的抗病毒预防以维持低HBVr风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Current and past hepatitis B virus (HBV) infection remains the leading cause of liver cancer in endemic areas. AIM: To examine the risk of HBV reactivation (HBVr) in patients receiving immune checkpoint inhibitors (ICI) for liver cancer. METHODS: Patients with current or past HBV infection receiving systemic treatments for liver cancer from March 2015 to March 2023 were identified using a territory-wide electronic database in Hong Kong. The primary outcome was HBVr in ICI compared to tyrosine kinase inhibitor (TKI) use, defined according to the American Association for the Study of Liver Diseases criteria. The secondary outcome was HBVr in different types of ICI. RESULTS: One thousand five hundred and ninty-six patients with current or past HBV infection (222 first received ICI; 1374 first received TKI) were included. 205 patients (12.8%) had past HBV infection, and 93.2% of the cohort were on HBV antiviral prophylaxis at baseline. At a median of 10.7 months (IQR: 3.7-12.0), 25 (1.6%) patients had HBVr, among whom 5 were exposed to ICI. The 12-month cumulative incidence (95% CI) of HBVr of the 1596 patients was 1.7% (1.1%-2.4%). The proportion of patients experiencing HBVr with and without antiviral prophylaxis was 1.4% and 3.7%, respectively. In multivariable analysis, ICI use was not associated with a higher risk of HBVr than TKI use, and the use of different ICI did not impact the risk of HBVr. CONCLUSION: With adequate antiviral prophylaxis, the absolute risk of HBVr is low in advanced HBV-related liver cancer patients receiving ICI, regardless of current or past HBV infection.
引用
- Yiu DC, Lai JC, Chan LL, et al. Comparative Risk of Hepatitis B Virus Reactivation in Patients Receiving Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitors for Liver Cancer. Aliment Pharmacol Ther. 2025. PMID: 40913340. doi:10.1111/apt.70367
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。